# MAGED4B

## Overview
MAGED4B is a gene that encodes the protein MAGE family member D4B, which is part of the melanoma-associated antigen (MAGE) family. This family of proteins is known for its involvement in various cellular processes, including cell cycle regulation and apoptosis, and is often associated with cancer due to its expression in tumor tissues. MAGE family member D4B is categorized as a cancer/testis antigen, which is typically expressed in a wide range of tumors but has limited expression in normal tissues, making it a potential target for cancer immunotherapy. The expression of MAGED4B has been linked to poor prognosis in several cancers, including glioma and breast cancer, where it may contribute to tumor progression and aggressiveness (Jia2019Prognostic; Arora2020Downregulation). Additionally, its role in head and neck squamous cell carcinoma has been explored in the context of DNA vaccine development, underscoring its potential as a therapeutic target (Wang2021DNA).

## Clinical Significance
MAGED4B, a member of the melanoma-associated antigen (MAGE) family, has been implicated in various cancers due to alterations in its expression levels. In glioma, MAGED4B is overexpressed, which is associated with poor prognosis and immune infiltration, suggesting its role in tumor progression (Arora2020Downregulation). The gene's elevated expression in glioma highlights its potential as a biomarker for this type of cancer, although specific clinical implications of MAGED4B mutations are not detailed (Arora2020Downregulation).

In breast cancer, MAGED4B expression is linked to worse recurrence-free survival, indicating a potential carcinogenic role (Jia2019Prognostic). This suggests that MAGED4B may contribute to tumor aggressiveness and could serve as a prognostic marker in breast cancer (Jia2019Prognostic).

MAGED4B is also expressed in head and neck squamous cell carcinoma (HNSCC), where it has been targeted in DNA vaccine studies. These vaccines have shown promise in inducing specific T cell responses and delaying tumor growth, highlighting MAGED4B's potential as a target for immunotherapy (Wang2021DNA). However, the clinical significance of MAGED4B mutations in these contexts remains to be fully elucidated.


## References


[1. (Wang2021DNA) Chuan Wang, Nur Syafinaz Zainal, San Jiun Chai, James Dickie, Chai Phei Gan, Natasha Zulaziz, Bryan Kit Weng Lye, Ruhcha V. Sutavani, Christian H. Ottensmeier, Emma V. King, Mannil Thomas Abraham, Siti Mazlipah binti Ismail, Shin Hin Lau, Thomas George Kallarakkal, Kein Seong Mun, Rosnah binti Zain, Zainal Ariff Abdul Rahman, Gareth J. Thomas, Sok Ching Cheong, Natalia Savelyeva, and Kue Peng Lim. Dna vaccines targeting novel cancer-associated antigens frequently expressed in head and neck cancer enhance the efficacy of checkpoint inhibitor. Frontiers in Immunology, October 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.763086, doi:10.3389/fimmu.2021.763086. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.763086)

[2. (Jia2019Prognostic) Binghan Jia, Xiaoling Zhao, Yao Wang, Jinlong Wang, Yingying Wang, and Yuemei Yang. Prognostic roles of mage family�members in breast cancer based on km‑plotter data. Oncology Letters, August 2019. URL: http://dx.doi.org/10.3892/ol.2019.10722, doi:10.3892/ol.2019.10722. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2019.10722)

[3. (Arora2020Downregulation) Mohit Arora, Sarita Kumari, Jay Singh, Anita Chopra, and Shyam S. Chauhan. Downregulation of brain enriched type 2 mages is associated with immune infiltration and poor prognosis in glioma. Frontiers in Oncology, December 2020. URL: http://dx.doi.org/10.3389/fonc.2020.573378, doi:10.3389/fonc.2020.573378. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2020.573378)